Table 2 Comparison of clinical features based on primary site of involvement
Characteristics | Â | Total cases (n = 581) | Small intestine (n = 162) | Ileocecal region (n = 231) | Large intestine (n = 125) | Multiple intestinal involvement (n = 63) | P value |
|---|---|---|---|---|---|---|---|
Age (years) | ≤ 60 | 356 (61.3) | 100 (61.7) | 146 (63.2) | 77 (61.6) | 33 (52.4) | 0.479 |
| Â | > 60 | 225 (38.7) | 62 (38.3) | 85 (36.8) | 48 (38.4) | 30 (47.6) | Â |
Sex | Male | 367 (63.2) | 108 (66.7) | 146 (63.2) | 73 (58.4) | 40 (63.5) | 0.557 |
| Â | Female | 214 (36.8) | 54 (33.3) | 85 (36.8) | 52 (41.6) | 23 (36.5) | Â |
Performance status | ECOG 0/1 | 490 (84.3) | 135 (83.9) | 197 (85.3) | 104 (83.2) | 54 (85.7) | 0.942 |
|  | ECOG ≥ 2 | 90 (15.5) | 26 (16.0) | 34 (14.7) | 21 (16.8) | 9 (14.3) |  |
| Â | Missing | 1 (0.2) | 1 (0.1) | Â | Â | Â | Â |
Serum LDH level | Normal | 355 (61.1) | 92 (56.8) | 152 (65.8) | 77 (61.6) | 34 (54.0) | 0.086 |
| Â | Increased | 210 (36.1) | 67 (41.4) | 71 (30.7) | 43 (34.4) | 29 (46.0) | Â |
| Â | Missing | 16 (2.8) | 3 (1.8) | 8 (3.5) | 5 (4.0) | Â | Â |
B symptoms | Absent | 459 (79.0) | 125 (77.2) | 185 (80.1) | 103 (82.4) | 46 (73.0) | 0.441 |
| Â | Present | 120 (20.7) | 36 (22.2) | 45 (19.5) | 22 (17.6) | 17 (27.0) | Â |
| Â | Missing | 2 (0.3) | 1 (0.6) | 1 (0.4) | Â | Â | Â |
Intestinal symptoms | Obstruction | 96 (16.5) | 25 (15.4) | 47 (20.3) | 14 (11.2) | 10 (15.9) | 0.267 |
| Â | Bleeding | 13 (2.2) | 2 (1.2) | 8 (3.5) | 3 (2.4) | 0 (0.0) | Â |
| Â | Perforation | 25 (4.3) | 8 (4.9) | 13 (5.6) | 3 (2.4) | 1 (1.6) | Â |
Extranodal involvement | < 2 | 417 (71.8) | 105 (64.8) | 179 (77.5) | 103 (82.4) | 30 (47.6) | < 0.001 |
|  | ≥ 2 | 155 (26.7) | 55 (34.0) | 47 (20.3) | 21 (16.8) | 32 (50.8) |  |
| Â | Missing | 9 (1.5) | 2 (1.2) | 5 (2.2) | 1 (1.0) | 1 (1.6) | Â |
IPI | L/LI | 277/151 (75.4) | 76/40 (71.6) | 129/48 (76.6) | 59/38 (77.6) | 13/25 (60.3) | < 0.001 |
| Â | HI/H | 87/53 (22.4) | 24/20 (27.2) | 33/15 (20.8) | 16/8 (19.2) | 14/10 (38.1) | Â |
| Â | Missing | 13 (2.2) | 2 (1.2) | 6 (2.6) | 4 (3.2) | 1 (1.6) | Â |
Lugano stage | I/II | 139/264 (71.1) | 37/73 (67.9) | 54/126 (77.9) | 43/54 (77.6) | 5/21 (41.3) | < 0.001 |
| Â | IV | 168 (28.9) | 52 (32.1) | 51 (22.1) | 28 (22.4) | 37 (58.7) | Â |
BM invasion | Absent | 494 (85.0) | 131 (80.9) | 199 (86.1) | 111 (88.8) | 53 (84.1) | 0.300 |
| Â | Present | 43 (7.4) | 17 (10.5) | 13 (5.6) | 6 (4.8) | 7 (11.1) | Â |
| Â | ND | 44 (7.6) | 14 (8.6) | 19 (8.2) | 8 (6.4) | 3 (4.8) | Â |
Immunophenotype | B-cell | 504 (86.7) | 131 (80.9) | 221 (95.7) | 106 (84.8) | 46 (73.0) | < 0.001 |
| Â | T-cell | 77 (13.3) | 31 (19.1) | 10 (4.3) | 19 (15.2) | 17 (27.0) | Â |